Poly A Poly U dsRNA for TLR3 Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical compositions of dsRNA are inefficient in activating both myeloid and epithelial cells for cancer treatment, often requiring transfection agents for cell penetration and having variable lengths that affect efficacy.
Innovation Solution
Development of short, synthetic dsRNA with predetermined lengths of 50 to 200 nucleotides, specifically composed of poly A and poly U blocks, which can activate myeloid cells and induce epithelial cancer cell death without the need for transfection agents, ensuring a high proportion of strands are of consistent length for enhanced efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If long dsRNA (200-8000 base pairs) is used, then TLR3 activation capability is maintained, but cell penetration efficiency decreases and requires transfection agents
Solution Approach 1:
The patent segments the long dsRNA into shorter fragments of 50-200 nucleotides. This segmentation allows the RNA to penetrate cells more efficiently without requiring transfection agents, while still maintaining the ability to activate TLR3. The shorter length enables passive cellular uptake while the specific sequence composition (poly A:poly U blocks) preserves TLR3 binding capability.
Solution Approach 2:
The patent changes the length parameter of dsRNA from 200-8000 base pairs to 50-200 nucleotides. This parameter change fundamentally alters the cellular uptake mechanism from requiring active transfection to allowing passive penetration, while the specific base composition (poly A:poly U in 1:1 ratio) compensates to maintain TLR3 activation efficacy.
2Ease of manufacture
If variable length dsRNA is used, then manufacturing is simpler, but activation efficacy becomes inconsistent
Solution Approach 1:
The patent establishes a specific length parameter range of 50-200 nucleotides with an optimal range of 60-120 nucleotides. This standardized length specification ensures consistent activation efficacy across different batches while remaining compatible with standard synthetic RNA production methods, thus balancing manufacturing simplicity with precision.
Solution Approach 2:
The patent specifies that within the 50-200 nucleotide length, the dsRNA should contain poly A and poly U blocks in a 1:1 ratio. This local compositional requirement ensures that even within the permitted length variation, the activation efficacy remains consistent by maintaining the critical poly A:poly U structural motif that binds TLR3.
3Reliability
If poly(I:C) is used, then TLR3 activation is achieved, but off-target activation of RIG-I, MDA5, and PKR occurs
Solution Approach 1:
The patent uses poly A and poly U blocks specifically arranged in a 1:1 ratio to create a local structural motif that is selectively recognized by TLR3. This specific compositional quality distinguishes the ligand from poly(I:C), which has a different base composition that cross-reacts with RIG-I, MDA5, and PKR. The poly A:poly U structure provides TLR3-specific activation without off-target effects.
Solution Approach 2:
Instead of using poly(I:C) that activates multiple receptors including TLR3, the patent inverts the approach by using poly A:poly U composition. This inverted base composition strategy achieves TLR3 activation through a different molecular recognition pathway, thereby avoiding activation of the cytosolic receptors RIG-I, MDA5, and PKR that are specific to poly(I:C).
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The short dsRNA compositions effectively activate myeloid cells, induce inflammation, and trigger apoptosis in epithelial cancer cells, providing a targeted and efficient cancer treatment approach.
Implementation Method 1
TLR3 is a pattern recognition receptor expressed mostly in endo-lysosomes that appears to be dedicated to the detection of viral infection through the binding of dsRNA
Data Source
AI summary
The invention relates to a composition comprising a double-stranded RNA (dsRNA) having two complementary strands, comprising at least one block of poly A and the complementary block of poly U, each strand having a length of between 50 and 200 bases, preferably between 55 and 200 bases, and a pharmaceutically acceptable vehicle, carrier or excipient, for use in a method of treating a cancer expressing a TLR3 receptor.